N/A
Completed N=1,086
Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
Secondary Immunodeficiencies (SID)
Source: ClinicalTrials.gov NCT04172467 ↗
Enrolled (actual)
1,086
Serious AEs
—
Results posted
Jan 2022
Primary outcomePrimary: Guideline Adherence (GLAD) — 889; 75; 122 Participants
Summary
Retrospective, representative registry for quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Guideline Adherence (GLAD) |
889; 75; 122 | — |
| SECONDARY Guideline Adherence and Susceptibility to Infection |
250; 63; 221 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- patients with CLL or MM
- anti-neoplastic systemic therapy (all therapy lines) between July 1st 2017 and June 30th 2018
Exclusion Criteria
- patient in terminal phase of the disease, life expectancy less than three months
Data sourced from ClinicalTrials.gov (NCT04172467). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.